Immunotherapy of melanoma: A critical review of current concepts and future strategies

Riker, Adam I., Radfar, Soroosh, Liu, Su Hu, Wang, Yixiang and Khong, Hung T. (2007) Immunotherapy of melanoma: A critical review of current concepts and future strategies. Expert Opinion on Biological Therapy, 7 3: 345-358. doi:10.1517/14712598.7.3.345


Author Riker, Adam I.
Radfar, Soroosh
Liu, Su Hu
Wang, Yixiang
Khong, Hung T.
Title Immunotherapy of melanoma: A critical review of current concepts and future strategies
Journal name Expert Opinion on Biological Therapy   Check publisher's open access policy
ISSN 1471-2598
1744-7682
Publication date 2007-03
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1517/14712598.7.3.345
Volume 7
Issue 3
Start page 345
End page 358
Total pages 14
Place of publication London, United Kingdom
Publisher Informa Healthcare
Language eng
Abstract Advanced melanoma is a devastating disease with a very poor overall prognosis. There are only two agents that are approved by the FDA for use in patients with metastatic melanoma: dacarbazine and IL-2. Both agents have an overall response rate well below 20%, with only rare long-term responders noted. Metastatic melanoma is known to be one of the most resistant cancers to a plethora of treatment modalities, such as single-agent and combination chemotherapy, chemoimmunotherapy and immunotherapy with a host of immune stimulators. Indeed, researchers worldwide have recognized the lack of effective therapies and have refocused their efforts on developing novel and cutting-edge strategies of treatment. This is based on an improved understanding of the complex interactions that occur within the tumor microenvironment, and the central role that the host immune system plays in the surveillance of cancer. This review summarizes the recent results of novel immunotherapeutic regimens and focuses on cutting-edge modalities of treatment that encompass new lines of thinking in the war against cancer and, in particular, melanoma.
Keyword Immunoadjuvant
Immunotherapy
Melanoma
Targeted therapy
Vaccines
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: ERA 2012 Admin Only
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 33 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 35 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sun, 11 Sep 2011, 12:45:22 EST by System User on behalf of School of Medicine